ABOUT US
11 px font size 12 px font size 14 px font size
Corporate Overview
Technology
Oral Delivery
Transdermal Delivery
Natural Human Proteins
Commercial Strategy
Leadership Team
Board of Directors
Scientific Advisory Panel
Careers
APOLLO NEWSLETTER
Professor Paul
Zimmet AO
Head of
International Diabetes Institute, Melbourne
"The data that I have seen so far makes this one of the most forward looking and best prospects of an oral insulin"
Click here to see Paul Zimmet's view on Apollo's oral insulin
Bill Moss AM
Non-Executive Director and
Investor
"Apollo has a number of opportunities to grow into the future. Opportunities perhaps that are much greater than many other companies many times their size"
Click here to hear Bill Moss's view on investing in Apollo
Commercial Strategy

Multiple & early sources of revenue
    Research Grade Proteins
    OTC

    Therapeutics
Risk Management
High Quality People Management

Apollo's strategic goal is to create, manufacture and market therapeutic products that satisfy unmet patient needs, using its oral and transdermal delivery platforms in combination with its library of more natural human proteins.

The company has several paths to commercialization, ranging from the research proteins market where it already sells products through to the longer-term development of therapeutics.

Apollo has a diversified product portfolio and has selected important markets where it can demonstrate the benefits of two proprietary technologies: the ability to deliver large proteins without needles, and its unique human-expressed proteins. These markets are related to one another in a way that allows Apollo to develop its products as a cluster of development opportunities.

Apollo's library of human-expressed proteins provides a diverse number of promising drug development candidates. Protein-based drugs (biopharmaceuticals) have application across many major disease and anti-ageing markets, including psoriasis, hepatitis C, rheumatoid arthritis, multiple sclerosis and Alzheimer's Disease. The oral and transdermal drug delivery platforms also have broad application, and are particularly powerful when combined with the protein library.

To select its priorities for therapeutic development, Apollo assesses candidates from its wide portfolio of potential targets, using the criteria of technological advantage and the value and growth of markets. Apollo's first two therapeutic candidates, which are proceeding through clinical trials, will enter markets with estimated annual revenues of over US$5 billion.

Apollo has put in place strategies to minimise risks to the company's future value, including:

  • cash generation in the early years
  • protection of value by not licensing too early
  • three platform technologies, each with broad application, to provide a deep portfolio of therapeutic candidates.
Multiple and early sources of revenue

The company's business model deliberately combines products, revenue types and timing to ensure early revenue-generating opportunities to protect growth in value of therapeutic candidates.

A key goal is to generate early sales revenue from two related product categories, well before therapeutic candidates complete the full clinical trial and regulatory approval process. The two early cash generating markets are:

  • research-grade recombinant human hcx™ proteins for use in research institutions and pharmaceutical and biotechnology companies
  • over-the-counter (OTC) products to improve appearance and ease inflammatory ailments.


These commercial market targets are spread across product sets which have different regulatory approval requirements. This leads to a natural staggering of points where Apollo's planned new products can generate revenue, from either sales or licence fees and royalty payments.
Research grade proteins market

Apollo has entered the research proteins market, which offers a relatively fast track to cash. This market can be targeted via the web, which is one of the industry's main distribution channels. The cost of initial development and supply is lower because the requisite level of purity is lower than for clinical therapeutic uses, and US Food and Drug Administration (FDA) and government approvals do not need to be obtained. Apollo is expanding its range of proteins and kits available for sale.
Over the counter/wellness market

The over the counter (OTC) and wellness market offers strategic benefits, because of lower regulatory requirements for OTC products and low-cost distribution channels through wholesalers and the internet. Apollo is initially developing products tailored to the needs of the baby boomer generation, to meet the increasing demand for products that delay the appearance of ageing and alleviate some inflammatory conditions. Apollo's transdermal delivery capability provides a natural extension into this market. Time frames to registration can be shorter than for the clinical therapeutic market. The company's first products will be launched under the Apollo Renewal brand in 2006, and Apollo may also license products.
Therapeutics market

Entering the therapeutics market is expected to offer significant commercial benefits. Biopharmaceutical treatment markets are large and growing and there is potential to license profitably to large global pharmaceutical companies. Apollo's commercial strategy is to develop its natural protein-based therapeutics with needle-free delivery through to Phase II clinical trials to provide evidence of the drugs' performance, as a basis for entering into licensing agreements with major industry players. Apollo's potential licensing or alliance partners are established corporate entities with global market reach, proven capacity to complete regulatory approval processes, and the ability to effectively market, distribute and sell on a global scale.
Risk Management

Apollo focuses on managing risk deliberately to maximise upside opportunity. This strategy is supported by a business model that simultaneously increases the number of revenue opportunities and reduces discovery, production and commercialisation risk. This ensures that success is more likely, cheaper and achieved sooner than might otherwise be the case.

Top
High quality people and management

Apollo ensures it has high quality scientists and senior management. Apollo emphasises supplementing rigorous science with a sound commercial discipline from early stages.

Apollo's scientists must mix good science with strong business discipline. We have developed processes to focus on outputs, innovation and problem-solving in a risk management framework. Apollo's success depends on taking advantage of our cross-discipline and cross-functional capabilities.

Top